Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lophenol (also known as 4α-methyllathosterol) is a naturally occurring phytosterol and tetracyclic triterpenoid isolated from *Aloe vera* gel and other plant sources. It serves as a key metabolic intermediate in the biosynthesis of plant sterols and the mammalian Kandutsch-Russell pathway for cholesterol synthesis. Research indicates that lophenol acts as an agonist of peroxisome proliferator-activated receptors (PPARs), specifically PPAR-alpha and PPAR-gamma, which regulate lipid and glucose metabolism. In preclinical models, lophenol has demonstrated anti-diabetic, anti-obesity, and hepatoprotective properties, and it has been evaluated in in silico and in vitro studies for its potential to inhibit pancreatic lipase, aldose reductase, and dipeptidyl peptidase-IV (DPP-IV). Additionally, as a component of Aloe sterols, it has been studied in clinical trials for improving skin elasticity, barrier function, and reducing facial wrinkles.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lophenol.